|
In an interview with CONICYT, Dr. Kalergis said that “this pioneering initiative is transformed into a phase I clinical study, the first for a vaccine developed by Chilean science and in compliance with all national and international regulations.” |
DR. ALEXIS KALERGIS
|
Dr. Alexis Kalergis, professor of the Pontificia Universidad Católica de Chile, developed in Chile a vaccine against the respiratory syncytial virus (RSV). This virus is the main cause of respiratory infectious diseases in children in Chile and the world. The vaccine has passed the pre-clinical and manufacture studies, and there is an agreement with the Health Department to ensure access to the vaccine for the entire population through the National Program of Immunization.
Also, in collaboration with Dr. Susan Bueno, Dr. Kalergis is developing a vaccine against the human metapneumovirus (HMPV), which causes respiratory infectious diseases, especially among children and older adults.
